VOLITIONRX LTD (VNRX): Unregistered Sales of Equity Securities
VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities As previously reported, pursuant to that certain securities purchase agreement dated May 15, 2025 (as amended and restated on January 7, 2026, the “SPA”), VolitionRx Limited (the “Company”) issued to Lind Global Asset Management X
How this was made
The 30-second read
Why it matters
The conversion adds several hundred thousand shares per tranche, modestly increasing share count and potentially pressuring the stock price.
Market read
Primary disclosure of a small‑scale dilution event; limited trading relevance.
What to watch
Potential future financing needs if conversion capacity remains high.
Background
VolitionRx Ltd filed a Form 8‑K disclosing unregistered sales of equity securities resulting from conversions of senior secured convertible promissory notes.
Ticker impact
8‑K filing reports issuance of multiple share tranches (~4.5 M shares) to Lind Global Asset Management under convertible notes.
Potential modest downward pressure as new shares increase supply.
Dilution is small in absolute terms but may affect share price perception.
Market effects
Limited impact on the biotech/pharma sector; similar convertible note conversions are common.
No significant regional effect; the filing is company‑specific.
Minimal global relevance.
Counterpoint
Investors may view the dilution as a sign of cash‑flow needs, suggesting caution.
Key entities
- CompanyVolitionRx Ltd
Biopharma company issuing shares under convertible notes.
- InvestorLind Global Asset Management XII LLC
Holder of the convertible notes receiving the shares.
